<DOC>
	<DOCNO>NCT01200472</DOCNO>
	<brief_summary>STUDY DESIGN : This phase 2 , multicenter , randomize , double-blind , placebo-controlled , parallel-group , efficacy safety study 30 patient erosive osteoarthritis interphalangeal joint . The study compose 4 phase : pre-randomization phase 35 day follow 91-day randomized , double-blind two arm treatment phase , follow 77-day open label treatment phase study participant 28-day observational follow-up phase . Efficacy double blind open label phase assess study day 84 168 treatment start respectively . STUDY DURATION : The study length approximately 231 day individual patient . With approximately 12 month recruitment period study plan last January 2010 July 2011 ( 19 month ) . STUDY OBJECTIVES : The primary objective evaluate 84-day efficacy apremilast 20 mg twice per day [ BID ] , subsequent 7-day dose titration , compare placebo , treatment symptom erosive hand osteoarthritis . Further objective evaluate effect pain , disease activity , structural damage , quality life , safety tolerability .</brief_summary>
	<brief_title>Efficacy Study Apremilast ( CC-10004 ) Subjects With Erosive Hand Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must least two bone erosion detectable conventional radiograph hand first carpometacarpal joint ( CMC ) , proximal and/or distal interphalangeal joint Must active disease screen randomization least two swollen tender PIP and/or DIP joint ; two joint affect screen randomization . Must patient self assessment pain baseline least 40 % VAS Must negative rheumatoid factor ( RF ) antiCCP antibody Must able adhere study visit schedule protocol requirement Male subject ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity Females Childbearing Potential ( FCBP ) study medication least 28 day take last dose study medication Females childbearing potential ( FCBP ) must negative urine pregnancy test Screening Baseline must willing use one highlyeffective form birth control engage reproductive sexual activity study medication least 28 day take last dose study medication ( § A female childbearing potential sexually mature female 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) 2 ) postmenopausal least 24 consecutive month ( ie , menses time precede 24 consecutive month ) . Must meet follow laboratory criterion : Hemoglobin ≥ 9 g/dL Hematocrit ≥ 27 % White blood cell ( WBC ) count ≥ 3000 /μL ( ≥ 3.0 X 109/L ) ≤ 14,000/μL ( &lt; 14 X 109/L ) Platelets ≥ 100,000 /μL ( ≥ 100 X 109/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Total bilirubin ≤ 2.0 mg/dL Aspartate transaminase ( AST , SGOT ] ) alanine transaminase ( ALT , SGPT ] ) ≤ 1.5x upper limit normal ( ULN ) Exclusion criterion : History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major disease History clinically significant inflammatory disease EHOA , especially , limited , rheumatoid arthritis spondylarthropathies History Diagnosis Fibromyalgia Evidence gout , pseudogout hemochromatosis Any injury , medical surgical procedure affect joint ( ) may interfere evaluation target hand OA joint ( ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant lactate female History active Mycobacterium tuberculosis infection within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treated History incompletely treat latent Mycobacterium tuberculosis infection ( indicated positive Purified Protein Derivative [ PPD ] skin test vitro test ( QuantiFERON Gold® ) . History infect joint joint prosthesis within past 5 year Any antiinflammatory immunosuppressive therapy condition include , limited , glucocorticoid , methotrexate , sulfasalazine , leflunomide , chloroquine , hydroxychloroquine , gold compound , parenteral corticosteroid , penicillamine , cyclosporine , oral retinoids , mycophenolate mofetil , thioguanine , hydroxyurea , sirolimus , tacrolimus azathioprine within 35 day randomization throughout study Use NSAIDs within 35 day randomization throughout study Intraarticular corticosteroid target joint within three month prior randomization Intraarticular injection hyaluronate target joint within six month prior randomization Use investigational medication within 35 day prior randomization 5 halflives know ( whichever longer ) Use `` nutraceuticals '' alternative medicine product , unless take stable dose minimum three month prior randomization Any clinically significant abnormality 12lead ECG screening determine investigator History malignancy within previous 5 year ( except treat basalcell skin carcinoma and/or squamouscell skin carcinoma ) Highrisk factor ( ) , history , human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C virus infection Have know history serious infection ( eg , hepatitis , pneumonia , pyelonephritis ) previous 3 month Have history alcohol substance abuse within precede 6 month , opinion investigator , may increase risk associate study participation study agent administration , may interfere interpretation result Have participate study Patients underage incapable understand aim , importance consequence study give legal inform consent ( accord § 40 Abs . 4 § 41 Abs . 2 und Abs . 3 AMG ) . Patients possibly dependent sponsor investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>EHOA</keyword>
</DOC>